Brief: Liminal BioSciences Doses First Subject In Phase 1A Trial Of Fezagepras
23/05/2022 13:49
May 23 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES ANNOUNCES FIRST SUBJECT DOSED IN PHASE
1A
SINGLE ASCENDING DOSE CLINICAL TRIAL OF FEZAGEPRAS
Source text for Eikon: ID:nCNWvCY0Ja
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy